Neuropore Therapies, Inc. and UCB entered into a collaborative partnership in 2015 for the clinical development of NPT200-11 as a disease modifying treatment option for people living with Parkinson's disease. UCB is a global biopharma focused on severe diseases with operations in approximately 40 countries.

Neuropore Therapies, Inc. and BenevolentAI® completed a collaboration in 2019 to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The collaboration aims to discover small molecule therapeutics for multiple AI-identified molecular targets using Neuropore’s Autophagy Platform. 

The Michael J. Fox Foundation currently supports the Neuropore TLR2 antagonist program, aimed at reducing pathogenic neuroinflammation in Parkinson’s disease. The 2017 and 2018 grant awards are in support of in vitro and in vivo activities essential for the development and advancement small molecule TLR2 antagonists. Additionally, the Michael J. Fox Foundation has supported the pre-clinical development of NPT200-11, our alpha synuclein misfolding inhibitor program now partnered with UCB Pharmaceuticals, which currently is in clinical development as a disease-modifying therapy for Parkinson’s disease. We thank the Foundation for their continued support of Neuropore programs focused on mitigating the progression of Parkinson’s disease.

Neuropore Therapies, Inc. collaborated with the research teams of Ana Maria Cuervo and Esperanza Arias-Peres to explore the therapeutic potential of macroautophagy- and chaperone-mediated autophagy- -modulating small molecules to restore proteostasis in central and peripheral cellular systems.

Neuropore Therapies, Inc. is collaborating with the research teams of Nicolas Dzamko and Glenda Halliday to explore the therapeutic potential of inflammation-modulating small molecules in mitigating alpha synuclein-induced toxicity in human induced pluripotent stem cell-derived neurons and in pre-clinical animal models of Parkinson’s disease.

Neuropore Therapies, Inc. collaborated with the research teams of Guenter Hoeglinger and Matthias Hoellerhage to explore the therapeutic potential of macroautophagy-, chaperone-mediated autophagy- and inflammation-modulating small molecules in mitigating alpha synuclein-induced toxicity in human neurons.

Neuropore Therapies, Inc. was founded by Dr. Eliezer Masliah and colleagues from the UCSD School of Medicine. Neuropore continues to maintain active collaborations with UCSD, gaining new insights into the mechanisms of neurodegenerative disorders and how they can be treated.